Efficacy and safety of the interleukin-10–fragment F8 fusion protein PF-06687234 as add-on therapy to infliximab in patients with active ulcerative colitis: a randomized, phase IIa clinical trial
Therapeutic Advances in Gastroenterology
Published online on February 10, 2026
Abstract
Therapeutic Advances in Gastroenterology, Volume 19, January-December 2026.
Background:PF-06687234 is a novel, human, single-chain variable fragment cytokine fusion protein comprising the antibody fragment F8 and the immunoregulatory cytokine interleukin-10.Objectives:We evaluated the efficacy and safety of PF-06687234 as an add-...
Background:PF-06687234 is a novel, human, single-chain variable fragment cytokine fusion protein comprising the antibody fragment F8 and the immunoregulatory cytokine interleukin-10.Objectives:We evaluated the efficacy and safety of PF-06687234 as an add-...